Both all speakers are requested to make the poster.
Please kindly check the detail on page.
Registration IDDate of Presentation

id001

12/8 17:05-18:35

id002

12/9 11:00-12:00

id003

12/8 17:05-18:35

id004

12/8 17:05-18:35

id005

12/8 17:05-18:35

id006

12/8 17:05-18:35

id007

12/8 17:05-18:35

id008

12/9 11:00-12:00

id009

12/9 11:00-12:00

id011

12/9 11:00-12:00

id012

12/8 17:05-18:35

id013

12/8 17:05-18:35

SessionModerated Poster 1(ex-Oral Presentation 1)
Moderated Poster 2(ex-Oral Presentation 2)Moderated Poster 1(ex-Oral Presentation 1)
Moderated Poster 1(ex-Oral Presentation 1)
Moderated Poster 1(ex-Oral Presentation 1)
Moderated Poster 1(ex-Oral Presentation 1)
Moderated Poster 1(ex-Oral Presentation 1)
Moderated Poster 2(ex-Oral Presentation 2)
Moderated Poster 2(ex-Oral Presentation 2)
Moderated Poster 2(ex-Oral Presentation 2)
Moderated Poster 1(ex-Oral Presentation 1)
Moderated Poster 1(ex-Oral Presentation 1)
Moderated Poster 1

id014

12/8 17:05-18:35

id015

12/8 17:05-18:35

id016

12/9 11:00-12:00

id017

12/8 17:05-18:35

id018

12/9 11:00-12:00

id019

Display only

Unmoderated Poster

id020

Display only

Unmoderated Poster(ex-Oral Presentation 1)
Moderated Poster 1(ex-Oral Presentation 1)
Moderated Poster 2(ex-Oral Presentation 2)
Moderated Poster 1(ex-Oral Presentation 1)
Moderated Poster 2(ex-Oral Presentation 2)

Moderated Poster 2

id021

12/9 11:00-12:00

id022

12/8 17:05-18:35

id023

Display only

Unmoderated Poster

id024

Display only

Unmoderated Poster(ex-Oral Presentation 2)
Moderated Poster 1(ex-Oral Presentation 1)

Moderated Poster 2

Presentation

Title of Abstract

Order1

A mitochondria-targeted drug induces apoptosis in prostate cancer xenografts

8Biology and usefulness of [-2]proPSA as a prognostic marker in CRPC patients

3Combination therapy with novel androgen receptor antagonists and statin for castration‐resistant prostatecancer

13Novel Nomogram Predicting Biochemical Recurrence-Free Survival After Radical Prostatectomy

5

GDF15 propeptide is a novel and useful biomarker for bone metastases in prostate cance4

Lipopolysaccharide from dysbiotic gut microbiome promotes prostate cancer growth through histamine H1receptor signaling7

Is 12 Systemic Cores in Transperineal Biopsy Sufficient for Detecting Clinically Significant Prostate Cancer?

4Switching to darolutamide for M0CRPC resistant to enzalutamide or apalutamide

57912Efficacy and Safety of Enzalutamide and Apalutamide in the Treatment of Patients with nmCRPC: A
retrospective analysis
Cisplatin and Etoposide for treatment-related Neuroendocrine Prostate Cancer: avorable early Response withshort Duration
Clinicopathological analysis of prostate cancer with lymph node metastasis in the prostatic anterior fat pad
Comparison of longitudinal health‐related QOL outcomes between anterior and posterior approaches torobot‐assisted radical prostatectomy

11Ealry outcomes of Single port robotic radical prostatectomy : 1 year followed up

14Carbon-ion radiotherapy for high-risk prostate cancer in Gunma University Heavy Ion Medical Center

3

PSA doubling time predicts the efficiency of site-directed therapy for non-metastatic or oligometastatic CRPC

15

Salvage low-dose rate brachytherapy for local recurrence of prostate cancer after radical radiotherapy

9The Effects of Personal and Family Cancer History on the Diagnosis of Prostate Cancer in a Multi-Institutional
Prostate Biopsy Registry
The Association of Anatomical Structural with Voiding Functions in Men with Benign Prostatic Hyperplasia/Lower Urinary Tract Symptoms
Role of the Elastography Strain Ratio using Transrectal Ultrasonography in the Diagnosis of ClinicallySignificant Prostate Cancer

2The Association between Human Gut Microbiota and Benign Prostatic Hyperplasia

8The Impact of mpMRI on Treatment Strategy for Incidental Prostate Cancer after HoLEP
Clinical Utility of Confirmatory Transperineal Template-Guided Saturation Prostate Biopsy after TRUS-Bx onTreatment Outcome of Focal HIFU
The characteristics of patients with prostate specific antigen persistence after Robot Assisted RadicalProstatectomy

id025

12/9 11:00-12:00

id026

12/8 17:05-18:35

id027

12/8 17:05-18:35

id028

Display only

Unmoderated Poster

Periprocedural adverse events and distribution of the SpaceOAR hydrogel for radiothrapy for prostate cancer

id029

Display only

Unmoderated Poster

How to deal with PI-RADS category3 cases?

id030

Display only

Unmoderated Poster

MRI-TRUS Fusion Biopsies: 30 cases of primary experience

id031

12/9 11:00-12:00

id032

Display only

(ex-Oral Presentation 2)
Moderated Poster 1(ex-Oral Presentation 1)
Moderated Poster 1(ex-Oral Presentation 1)

Moderated Poster 2(ex-Oral Presentation 2)

1

6106id033

12/8 17:05-18:35

id034

12/9 11:00-12:00

id035

Display only

Unmoderated Poster

id036

Display only

Unmoderated Poster(ex-Oral Presentation 1)
Moderated Poster 2(ex-Oral Presentation 2)

Circulating tumor cell based transcriptomic differences between localized and metastatic prostate cancer<br>Robotic-Assisted Simple Prostatectomy using the da Vinci SP system, pilot study

How I recruit the suitable nmCRPC patients for taking insurance-reimbursed Darolutamide in Taiwan
Clinical Analysis of Intensity modulated radiation therapy(IMRT) for localized prostate cancer at Showa

Unmoderated Poster
Moderated Poster 1

Changes of resistance indices after medication in benign prostatic hyperplasia: a prospective study

University
2

10Hyperforin Induces Extrinsic/Intrinsic Apoptosis Signaling and Inhibits NF-кB for Metastasis Suppression in
Prostate Cancer Cells
Risk of urinary tract infection in prostate cancer patients who treated with radiation therapy or radical
prostatectomy
Immune checkpoint molecules-targeting recombinant dendritic cells for therapeutic effect on prostate cancer
Robot-assisted laparoscopic radical prostatectomy (RARP) induction results and comparison with open radicalorostatectomy(ORR)